---
title: "HUTCHMED (China)  (HCM) Receives a Buy from SPDB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279142813.md"
description: "In a report released on March 13, from SPDB maintained a Buy rating on HUTCHMED (China) , with a price target of HK$28.00. The company’s shares closed last Friday at HK$22.08.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential HUTCHMED (China) has an analyst consensus of Strong Buy, with a price target consensus of p294.11."
datetime: "2026-03-15T05:45:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279142813.md)
  - [en](https://longbridge.com/en/news/279142813.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279142813.md)
---

# HUTCHMED (China)  (HCM) Receives a Buy from SPDB

In a report released on March 13, from SPDB maintained a Buy rating on HUTCHMED (China) , with a price target of HK$28.00. The company’s shares closed last Friday at HK$22.08.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

HUTCHMED (China) has an analyst consensus of Strong Buy, with a price target consensus of p294.11.

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)
- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [HUTCHMED says Phase II fanregratinib trial in FGFR2-altered bile duct cancer posts 42.5% response rate](https://longbridge.com/en/news/290751439.md)
- [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md)
- [China closing in but US still leads in biotech innovation, survey finds](https://longbridge.com/en/news/290431706.md)
- [The wrong prescription for drug affordability](https://longbridge.com/en/news/289929515.md)
- [Pharma giants commit $500B to US amid tariff threat](https://longbridge.com/en/news/289866895.md)